REACH Separations has entered a strategic alliance with Evotec to provide additional purification and analytical services to support Evotec’s pharma and biopharma clients worldwide. REACH Separations will serve as a technology partner to Evotec, responsible for providing expertise in small molecule chromatography. The companies are expanding upon their first partnership dating back to 2012.
Peter Ridgway, business development director at Reach Separations, said, “We are delighted to have struck a collaboration with one of the world’s leading drug discovery research organizations. Given the existing scientific knowledge available within the team at Evotec, this deal demonstrates the high level of purification and analytical expertise we are able to bring to such projects.To support the increasing workload this new partnership brings, we have invested in expanded lab space, taken on more scientists and increased our instrumentation capability ensuring we are consistently able to deliver not only for Evotec and its clients but for our developing client base as a whole.”
Dr. David Hallett, executive vice president of discovery chemistry at Evotec, said, “The team at Reach Separations has considerable expertise in the fields of chiral, reverse phase and normal phase chromatography that will help our in-house team with added expertise and resource.By adding Reach Separations to our exclusive portfolio of technology partners, it will allow us to streamline our processes that will allow us to meet clients’ project milestones even quicker.”